The number of targeted therapies available for the treatment of different cancers increases annually. However, for many of these agents, we do not have effective predictive biomarkers. The result is that patients who might benefit for certain therapies are not receiving them, and patients receive therapies from which they receive no benefit. In many cases, it is likely that an individual drug might be effective in only a small subset of a particular cancer, so that without a validated predictive biomarker, introduction to that cancer is impossible. W propose a novel and generalizable functional predictive biomarker approach, based on measuring death signaling early in the response to targeted therapies. We hypothesize that if we could identify those cancer cells that induce the strongest activation ofthe mitochondrial apoptotic pathway at early time points in response to a drug, we could thus identify those tumors that are most likely to respond in vivo. We are greatly assisted in this approach by our development of a novel tool, BH3 profiling, which can measure a cell's proximity to the threshold of apoptosis. Our approach is to treat cells with drugs, measure at short time points the extent to which apoptotic signaling is forcing cells toward the threshold of apoptosis, a method we call Dynamic BH3 Profiling. As we will show, we are now adept at making such measurements. Moreover, we already have exciting preliminary data that suggests that those cells that are pushed the most are also those that are destined to choose death as a cell fate. We propose to develop Dynamic BH3 profling first in AML cell lines, and then in murine AML primagrafts. Our output will be a set of drugs for which we have validated Dynamic BH3 profiling as a predicitve biomarker in vivo. These drugs might be useful as single agents, or as agents to increase priming to enhance sensitiity to conventional, curative agents. Acute myelogenous leukemia (AML) is an attractive disease in which to test our ideas because of our established expertise, established relationships, and access to clinical samples. Dynamic BH3 profling has the potential to expand the pharmacopeia and personalize therapeutic decision making for the AML patient.

Public Health Relevance

The number of Innovative targeted therapies for cancer is increasing. However, oncologists still do not have the information they need to make sure that individual cancer patients are being matched with the targeted therapies that best meet their needs. In this application we propose a novel approach, dynamic BH3 profling, to personalizing cancer therapy by measuring changes in cancer cells induced by targeted therapies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Brigham and Women's Hospital
United States
Zip Code
Hanoun, Maher; Zhang, Dachuan; Mizoguchi, Toshihide et al. (2014) Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche. Cell Stem Cell 15:365-75
Adamia, Sophia; Bar-Natan, Michal; Haibe-Kains, Benjamin et al. (2014) NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood 123:2816-25
Heckl, Dirk; Kowalczyk, Monika S; Yudovich, David et al. (2014) Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol 32:941-6
Adamia, Sophia; Haibe-Kains, Benjamin; Pilarski, Patrick M et al. (2014) A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clin Cancer Res 20:1135-45
Bruedigam, Claudia; Bagger, Frederik O; Heidel, Florian H et al. (2014) Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Cell Stem Cell 15:775-90
Santos, Margarida A; Faryabi, Robert B; Ergen, Aysegul V et al. (2014) DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier. Nature 514:107-11
Schneider, Rebekka K; Ademà, Vera; Heckl, Dirk et al. (2014) Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell 26:509-20
Liu, Suiyang; Yin, Li; Stroopinsky, Dina et al. (2014) MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. Blood 123:734-42
Liss, Adam; Ooi, Chia-Huey; Zjablovskaja, Polina et al. (2014) The gene signature in CCAAT-enhancer-binding protein * dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors. Haematologica 99:697-705
Ng, C E L; Sinha, A; Krivtsov, A et al. (2014) KRas(G12D)-evoked leukemogenesis does not require *-catenin. Leukemia 28:698-702

Showing the most recent 10 out of 218 publications